

# JOURNAL OF INVESTIGATIVE DERMATOLOGY

## INFORMATION FOR AUTHORS

**Lowell A. Goldsmith, MD, MPH, Editor**

JID Editorial Office  
Department of Dermatology  
University of North Carolina at Chapel Hill  
3100 Thurston Bowles Building, CB# 7287  
Chapel Hill, NC 27599-7287 USA  
Phone: 919-843-3094  
Fax: 919-843-3098  
Email: JID@med.unc.edu  
Manuscript submission website: <http://jid.manuscriptcentral.com>

### Journal Websites:

<http://www.jidonline.org>  
<http://www.blackwellscience.com/jid>

### I. SCOPE

*The Journal of Investigative Dermatology* publishes papers describing original research relevant to all aspects of cutaneous biology and skin disease. The spectrum of interest is indicated by the breadth of the editorial board and includes biochemistry, biophysics, carcinogenesis, cellular growth and regulation, clinical research, development, epidemiology and other population-based research, extracellular matrix, genetics, immunology, melanocyte biology, microbiology, molecular and cell biology, pathology, pharmacology and percutaneous absorption, photobiology, physiology, and structure. Original articles, Communications, Mutation Reports, Review articles and Letters to the Editor are standard features. Methods papers are eligible for publication if they are judged to describe important techniques of general interest to readers.

### II. EDITORIAL POLICIES

The Journal subscribes to the Uniform Requirements for Manuscripts Submitted to Biomedical Journals, as outlined in the International Committee of Medical Journal Editors website ([www.icmje.org](http://www.icmje.org)) and published in *Ann Intern Med* 126:36-47, 1997.

Manuscripts must be written in English. All data, text, figures and tables must be original and must not be published or submitted for publication elsewhere. Manuscripts will be accepted on the condition that nonproprietary unique reagents described (e.g., cells, antibodies, DNA) and survey instruments are made available to qualified scientists when feasible. In general, no submitted material will be returned to the authors.

**Peer Review** Manuscripts submitted to the *JID* will be evaluated by at least two reviewers, one of whom will be a *JID* Editorial Board member. The identity of reviewers is confidential and manuscripts are considered to be privileged information. Papers may be rejected without external review if the Editors decide the subject material is inappropriate for the *JID*'s audience.

**Revisions & Rebuttals** *JID* editorial policy allows for 1 revision of a manuscript, and revisions are due within 2 months of receipt of the decision letter. Manuscripts not received within this time will be dated and treated as new submissions. If after reconsideration the manuscript is not suitable for publication with only minor editorial changes, the paper must be resubmitted as a new manuscript to be reconsidered. Rejected manuscripts may be resubmitted for consideration if significant new data is presented. In such cases, the paper will be given a new manuscript number and date of receipt, and it will be treated as a new manuscript. Editorial decisions are rarely reversed. However, authors with serious concerns about potential scientific errors in the review process may send a rebuttal letter to the editor. Only written appeals will be considered.

**Supplemental Data** At the Editors discretion, large tables, data sets, etc. may be published as supplemental data on the *JID* website only.

**Embargo Policy** All accepted articles are embargoed until the publication date.

### III. Responsibilities of Authors

**Scientific Integrity** All submissions to and publications in the *JID* are assumed to be the products of honest observations. By submission, the first and senior authors take full responsibility for the integrity of the work as a whole, from inception to the published article. If substantial doubts arise regarding the scientific integrity of any submission or publication it is the responsibility of the Editor to pursue these issues with the author(s). The first and senior authors are responsible for communicating with the editorial office on issues of scientific misconduct or the retraction of a published manuscript, should questions of this type arise. Issues of scientific integrity include but are not limited to duplicate submission and publication, falsification or fabrication of data and plagiarism. The editors reserve the right to initiate the retraction of a published manuscript, should it be deemed appropriate. If these issues cannot be resolved with the authors to the satisfaction of the Editor, the issue will be referred to the institution where the work was done and/or the funding agency for further investigation. If the work is deemed to be fraudulent the *JID* will print a retraction, preferably signed by all authors of the work in question. Alternatively, the Editor may choose to print an expression of concern regarding the work, with explanation.

**Authorship Conditions** By submission, the first and senior authors take full responsibility for the integrity of the work as a whole, from inception to the published article. Each author should have participated sufficiently in the intellectual content of the work to take public responsibility for appropriate portions of its

content. Authorship credit should be based on: 1) conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting or revising the manuscript critically for important intellectual content; 3) final approval of the version to be published. Conditions 1, 2 and 3 must all be met. The contributions of those who do not meet these authorship requirements may be acknowledged in the Acknowledgments section of the manuscript.

**Changes in Authorship** Any changes in authorship must be communicated to the Editor in a letter signed by all authors.

**Conflict of Interest** Each author must indicate on the Declaration of Conflict of Interest Form whether they have financial, equity, patenting or other relevant relationships or arrangements with a product or sponsor of research that might constitute a conflict of interest. More information on conflict of interest can be found on the form and in the Uniform Requirements for Manuscripts Submitted to Biomedical Journals, by the International Committee of Medical Journal Editors ([www.thelancet.com/newlancet/sub/author/uniform1.html](http://www.thelancet.com/newlancet/sub/author/uniform1.html)). The editors may decide to indicate conflict of interest in the publication of the article. Sources of support should be indicated in the Acknowledgments.

**Copyright Transfer** The Transfer of Copyright Agreement, signed by all authors, must accompany all manuscript submissions. Note that no editorial decision will be communicated to the corresponding author before the receipt of the Declaration of Conflict of Interest, Transfer of Copyright Agreement, and the manuscript submission fee (see VA below). In addition, the official submission date will be the date on which the Editorial Office receives all these materials.

### Corresponding Author Responsibilities

- The corresponding author must state in the covering letter that 1) the data in the manuscript is original and that the paper is not under consideration elsewhere; 2) none of its contents have been previously published; 3) all authors have read and approved all versions of the manuscript, its content, and its submission to the *JID*.
- The corresponding author must submit a Copyright Transfer Agreement and Declaration of Conflict of Interest form signed by all authors, with signatures identified.
- Any changes in authorship must be communicated to the editorial office in writing in a letter signed by all original authors.
- Upon acceptance, the Corresponding Author will be asked to provide the editorial office with a disk containing the text of the manuscript in a Word or other document file, one hard copy of the manuscript text, and one complete set of original glossy figures sized at 100% of that desired for publication, at either 1- or 2-column widths. Failure to provide these materials will result in a delay in publication. Author proofs and queries will be sent to the Corresponding Author by email, and will require a two-day turnaround. No substantive changes may be made in the proof stage without the written approval of the Editor.

### IV. ETHICS

The authors' Institutional Review Board must have approved human in vivo and all animal studies. This should be mentioned in the Methods section of the manuscript. All patients referred to in human studies should be identified by number, not by name. All clinical investigation must have been conducted according to Declaration of Helsinki principles (<http://www.wma.net>). This should be mentioned in the Methods section of the manuscript. The editors reserve the right to reject manuscripts that fail to meet these criteria, and to ask for Institutional Review Board approval.

Identifying information should not be published in written descriptions, photographs and pedigrees unless the information is essential for scientific purposes and the patient (or parent or guardian) gives written informed consent for publication. Where informed consent has been obtained it should be indicated in the Methods section of submitted manuscript.

### V. MANUSCRIPT SUBMISSION

Please note that complete submissions contain all items below, and submissions are dated according to receipt of all items. No editorial decision will be communicated to the authors until the submission is complete.

#### A. ALL SUBMISSIONS MUST INCLUDE:

- Cover Letter stating
  1. The data in the manuscript is original and that the paper is not under consideration elsewhere
  2. None of its contents have been previously published
  3. All authors have read and approved all versions of the manuscript, its content, and its submission to the *JID*.
  4. If the submission contains color figures, the authors should state their willingness to pay color publication fees (estimated at \$550/color page), should the manuscript be accepted for publication.
  5. Corresponding author's address, telephone, fax, email (email address required, as all correspondence will be done electronically once manuscripts are loaded onto the *JID* submission website).
- Transfer of Copyright Agreement, signed by all authors.
- Declaration of Conflict of Interest, signed by all authors.
- Manuscript Submission Fee (\$50 for online submissions; \$125 for paper submissions; for details see below).

## B. ONLINE SUBMISSIONS (PREFERRED)

Authors with Internet connections should submit manuscripts, including figures, to the *JID* submission website (<http://jid.manuscriptcentral.com>). Loading instructions are given at this site. For assistance, contact Scholar One technical support at 434-817-2040 x 167 or email: [support@scholarone.com](mailto:support@scholarone.com).

**Submission fee:** When submitting manuscripts online, a manuscript submission fee of US \$50 should be paid online by credit card. If this is not possible, a check drawn on a US bank made out to "The Society for Investigative Dermatology" should be sent to the *JID* Editorial Office with an accompanying cover letter.

## C. PAPER SUBMISSIONS

Authors who cannot submit their manuscript online should send the following to the *JID* Editorial Office:

- Manuscript Submission Form
- Cover letter (see above)
- List of suggested referees (optional), including full name, address, telephone, fax, email
- One copy of the manuscript, double-spaced
- One copy of all illustrative material and tables in a separate envelope
- Figures labeled with Top, Figure #, First author name
- Manuscript on a 3.5-inch low- or high-density diskette, zip disc or CD-Rom (details at [www.jidonline.org/misc/ifofoa.shtml](http://www.jidonline.org/misc/ifofoa.shtml) or [www.blackwellscience.com/jid](http://www.blackwellscience.com/jid))
- \$125 submission fee (\$50 submission fee, plus \$75 fee for uploading to manuscript submission website). Payment may be made by credit card or by check made out to "The Society for Investigative Dermatology" and sent to the *JID* Editorial Office along with the submission.

## VI. MANUSCRIPT PREPARATION

### A. GENERAL

Manuscripts must be typed, and all text double-spaced, with wide (1" or larger) margins. Number all pages, with title as page 1. The paper should be concise, economical of references, figures and tables, and formatted as described below. Manuscripts of inappropriate length or format, or with excessive tables and figures, may be returned to the authors. Investigative studies should be organized as follows: Title page, Abstract, Introduction, Materials & Methods, Results, Discussion, Acknowledgments, References, Tables, Figure Legends.

### B. TITLE

The title page should include the following:

- Brief, informative title of 120 characters or less
- Authors' full names, departments, and institutions (indicate affiliations with symbols placed after authors' names and before the institutions)
- City, state and country in which the work was done
- Corresponding author's address, telephone, fax and email (email address required)
- Short title of 45 characters or less, including spaces
- Abbreviations used (see below for detail on abbreviations)
- Up to 5 keywords (MeSH terms if possible; ISRCTN if desired), for abstracting ([www.nlm.nih.gov/mesh/2K/99Mbrowser.html](http://www.nlm.nih.gov/mesh/2K/99Mbrowser.html))

### C. ABSTRACT

- Do not exceed 200 words
- Briefly summarize the background, purpose, results and conclusions of the study, in that order, without headings
- Do not include nonstandard abbreviations, acknowledgments of support, or refer to footnotes or references
- Write with a general scientific audience in mind

### D. INTRODUCTION

The article should begin with a brief introductory statement that places the work to follow in historical perspective and explains its intent and significance.

### E. MATERIALS AND METHODS

Readers should be able to reproduce the experiments from the information in the methods section, figure legends, table footnotes, and references. Provide the manufacturer's name and location (city, state within USA; country if outside USA) for materials purchased. Manuscripts must include a statement that all human and animal studies have been approved by the authors' Institutional Review Board (see details at #IV above), and, for human studies, that Declaration of Helsinki protocols were followed.

### F. RESULTS AND DISCUSSION

The Results section should briefly present the experimental data in text, tables or figures. The Discussion should focus on the interpretation and significance of the findings with concise objective comments that describe their relation to other work in the area. It should not repeat information in Results. Results and Discussion may be presented separately or combined into a single section.

### G. ACKNOWLEDGMENTS

A note of acknowledgment is appropriate recognition for contributors who may not be listed as authors, as well as for noting financial or other support of the research.

## H. REFERENCES

References should be presented on a separate sheet and listed alphabetically. To save space, the citation of appropriate recent review articles is encouraged. Only full-length papers or manuscripts in press should be cited in the references. List all authors, but in the case of eight or more authors, list only the first three, then use "et al." The style of references and abbreviations of journal names must conform to those adopted by the Index Medicus and must show inclusive page numbers. The names of unlisted journals should be spelled out. For specific examples, refer to articles in the Journal. For papers in press, give the title of the publication and the journal name. Unpublished citations such as theses, "personal communications," "in preparation," etc. should be given in parentheses in the text, and must be approved in writing by the individuals cited. Abstracts are not cited in the references but should be listed as footnotes in standard reference format, followed by the designation "(abstr.)". Refer to publications in the text as "(Schmidt and Jones, 2000)" or as "(Schmidt et al, 2000)" in the case of three or more authors.

If using Reference Manager, use *Cytogenetics & Cell Genetics* style

## I. FOOTNOTES

Footnotes should be listed consecutively at the foot of the page on which they fall, designated by superscript numbers (e.g., 1,2,3). References to abstracts or unpublished works must be given as footnotes to the text, not in the references.

## J. TABLES

Tables and their footnotes should be self-explanatory. Tables should be included with the figure set. The table number (in Roman numerals) should follow the sequence of citation in the text, and an informative, not descriptive, title should be supplied. Do not provide a table legend, but supply information such as the description of what experiment was performed and how, definition of columns or abbreviations, etc. in footnotes to the title and table contents. Define errors in the table by a footnote, e.g., "mean  $\pm$  SD" or "mean  $\pm$  SEM".

## K. FIGURES & FIGURE LEGENDS

**Authors who submit online** should load figures according to the instructions provided there. Scan in a graphics program – not Word or PowerPoint – at least 300 dpi.

**Authors who submit by mail** should submit one set of all glossy prints or laser-printer figures of high resolution and clarity, unmounted and in a separate envelope. Artwork will be returned only upon request. On the back of each figure indicate:

- Top of illustration
- Number of illustration
- Name of first author

Do not embed artwork in the manuscript. Figures should be intelligible without reference to the text; they should complement and not reiterate the text. Graphs in particular should be designed to take as little space as possible, while remaining easily legible. To avoid size reduction, authors should submit artwork of exact column measurements and crop out unnecessary areas (1 column = 19 picas; 2 columns = 40 picas). Most figures should be presented at 1 column width. Figures should be numbered in order of appearance. Parts of the figure, such as a, b, etc. should be labeled on the face of the figure in small lower case letters, but the title should be given in the legend, not on the figure. For examples see *J Invest Dermatol* 118: 779–788, 2002.

**Line drawings** should be clear, with lines of uniform thickness. Curves should be smooth. Do not use 3-dimensional graphs unless the third dimension is used for data. Label axes parallel to the axis. Use only black and white, not gray, in charts and graphs. The inside of bar graphs should use a patterned black and white print. Do not place borders around figures.

**Electronic Artwork** that has been generated by a computer or "digitized" should be accompanied by a computer file for that figure saved in TIFF or EPS format (at least 300 dpi). Be sure to adhere to the "Electronic artwork information for authors" ([www.blackwellpublishing.com/authors/digil.asp](http://www.blackwellpublishing.com/authors/digil.asp)).

**Figure Legends** should be presented on a separate page in the following form: **Figure 1.** A short informative title stating the meaning of the data shown. Legends should explain how an experiment was done and identify parts of the figure, not interpret the figure. In the online edition of the journal, figure legends may be truncated in abbreviated links to the full screen version. Therefore, the first 100 characters of any legend should inform the reader of key aspects of the figure. Use a single title for each figure (i.e., do not use separate titles for parts a, b, etc.). Next, indicate how the experiment was performed, without repeating information from Materials and Methods. Indicate the meaning of all symbols, keys and abbreviations used in the figure. Interpretive text should be placed in the text of the manuscript rather than in the figure legends.

**Photomicrographs:** A scale bar, not magnification, must be placed on micrographs and the scale indicated in the legend, e.g., "scale bar = mm". Error bars should be defined in the figure legend as "mean  $\pm$  SD" or "mean  $\pm$  SEM". If you use SEM give n for each point.

**Color Art:** The cost to authors for publishing color art is estimated at \$550 per page containing color art.

Authors submitting **online** should not upload figures in color if they should be published in black and white.

Authors submitting **color** art should enclose a letter agreeing to pay the color charges. Such agreement must be received by the Journal before the article can be accepted for publication. The artwork of published articles will not be returned.

#### L. ABBREVIATIONS

Terms used more than 5 times may be abbreviated and should be listed with their abbreviations on the title page. Abbreviations should conform to those listed in *Scientific Style & Format*, 6th ed. (Cambridge University Press, Cambridge, UK, 1994). Capitalize trade names, but use generic names if possible. The trivial names of chemicals may be used if the formal chemical name is given with the first use of the trivial name. Abbreviations are not allowed in the abstract.

#### VII. PAGE CHARGES

The Journal does not make the payment of page charges a condition for acceptance of a manuscript for publication. The authors will be assessed \$50 per printed page, but in extraordinary cases, upon appeal by the author **before publication of the article**, the Editor may waive the assessment. The cost to authors for publishing color art is \$550 per page.

#### VIII. SUBMISSION OF DNA SEQUENCES

Sequences must have an EMBL or Genbank database accession number, and this number should be given in the legend to the figure showing the sequence.

#### IX. COMMUNICATIONS

Authors may submit concise reports of work of unusual interest or importance with limited but definitive data for publication as a Communication. To be considered, the manuscript should not exceed four printed pages including all written material, figures, tables, and no more than 30 references.

#### X. MUTATION REPORTS

Mutation reports should be short manuscripts (not exceeding 2 journal pages, including figures and references). Mutation reports should include 1) an abstract of about 100 words; 2) description of the case; 3) documentation of the mutation, including evidence that the mutation is responsible for the condition. The manuscript should concentrate exclusively on the data, with little commentary about the literature except as pertains to the data reported.

Mutation Reports must fulfill the following criteria:

- 1) There must be evidence that the report deals with a mutation causing an abnormal phenotype;
- 2) The mutations should not only be novel but must provide new insight into structure or biologic function or be responsible for a phenotype hitherto not reported to be caused by the gene containing the mutation. Work on novel mutations for which there is reasonable evidence of causing an abnormal phenotype but that do not provide new insight into structure/function or gene/phenotype relationship and work on mutations that are analogous to published ones can be submitted as Letters to the Editor (see below). More detailed structure/function analyses may be submitted as regular reports.

#### XI. REVIEW ARTICLES

The Journal welcomes minireviews of three to four journal pages describing recent developments of interest to readers. Such reviews should not be extensive in nature or contain exhaustive references and should be accessible to readers not intimately familiar with the subject under review. They should serve to increase readers' interest and to point out important and exciting recent developments rather than to serve as an encyclopedic reference. Longer reviews will also be considered, and authors are encouraged to consult the editor before submission.

#### XII. LETTERS TO THE EDITOR

Letters to the Editor may report original data or may discuss published articles. Submission requirements for Letters to the Editor are the same as for regular manuscripts. Letters are not to exceed about 1000 words and two figures. Comments may be solicited from authors if the letter refers to an article in the Journal. Letters that report original data will be reviewed. All Letters to the Editor are subject to editing and possible abridgment.

#### XIII. ANNOUNCEMENTS

Brief announcements of scientific meetings, availability of fellowship grants, and awards for research relevant to the readership will be published at the discretion of the Editor if space permits. Announcements must reach the editorial office at least 8 weeks before their anticipated publication. In general, announcements will be published only once.

#### XIV. ARCHIVING

The Editorial Office will retain a single hard copy or electronic file of each manuscript for 6 months following the final editorial decision. Unless other instructions are provided by the author, it will be destroyed at that time.

## GENERAL INFORMATION

*The Journal of Investigative Dermatology* publishes original papers and reviews pertinent to the normal and abnormal function of the skin. The Journal is indexed and abstracted in *Biological Abstracts*, *Current Contents*, *Excerpta Medica*, *International Pharmaceutical Abstracts*, *Index Medicus*, *Nutrition Abstracts and Reviews*, and *Reference Update*. Electronic indexing is provided by MedLine (<http://igm.nlm.nih.gov/>), PubMed (<http://www.ncbi.nlm.nih.gov/entrez/>), ISI (<http://www.isinet.com/>) and CrossRef (<http://www.crossref.org/>)

©<sup>TM</sup> This paper meets the requirements of ANSI Standard Z39.48-1992 (Permanence of Paper).

**Subscription Information** Annual subscription rates for Volumes 120 and 121. Institutional Premium Rate\*: The Americas - \$713; Canada/Mexico\*\* - \$749; Rest of World\*\*\* - £558; Personal Rate\*: The Americas - \$487; Canada/Mexico\*\* - \$521; Rest of World\*\*\* - £397

\*Includes print plus premium online access to the current and all available backfiles. Print and online-only rates are also available (see below)

\*\*Customers in Canada should add 7% GST or provide evidence of entitlement to exemption

\*\*\*Customers in the UK should add VAT at 5%; customers in the EU should also add VAT at 5%, or provide VAT registration number or evidence of entitlement to exemption.

For more information about Blackwell Publishing journals, including online access information, terms and conditions, and other pricing options, please visit <http://www.blackwellpublishing.com> or contact our customer service department, tel: 1 800 835-6770 or +1 781 388-8206 (US Office) +44 (0)1865 251866 (UK Office). Subscription, including postage, for members of The Society for Investigative Dermatology, Inc. (SID) and the European Society for Dermatological Research (ESDR) is included in the annual dues. Individuals who are members of both societies may deduct the subscription rate of \$93 from the annual dues for the SID if they are primary members of the ESDR and vice versa.

**Applications for Society Membership and Resident Subscriptions** For the SID, contact Angela Welsh, Administrative Director, Society for Investigative Dermatology, Inc., Suite 340, 820 West Superior Avenue, Cleveland, OH 44113-1800 (email: [welsh@sidnet.org](mailto:welsh@sidnet.org)); for the ESDR, contact Thomas Florestan, Administrative Director, ESDR, Room 4-794, Department of Dermatology, Geneva University Hospital, 24 rue Micheli-du-Crest, 1211 Geneva, Switzerland (email: [office@esdr.ch](mailto:office@esdr.ch)).

Back Issues are available from the publisher at the current single issue rate.

**Correspondence** regarding non-member subscriptions, single copies, back issues, and claims for missing issues should be sent to the Journal Fulfillment Department, Blackwell Publishing, Inc., Commerce Place, 350 Main Street, Malden, MA 02148. Both the Publisher and the SID or ESDR must be notified 60 days in advance of change of address.

**Advertising** Although all advertising material published in the Journal is expected to conform to ethical medical standards, acceptance does not imply endorsement by the SID or by the ESDR. Please direct inquiries regarding the placing of advertising in the *Journal* to Gene Conselyea (email: [gconselyea@pminy.com](mailto:gconselyea@pminy.com)) or Kathy Clark (email: [kclark@pminy.com](mailto:kclark@pminy.com)) Pharmaceutical Media, Inc., 30 E. 33rd Street New York, NY 10016; Tel: 212 685 5010; Fax: 212 685 6126. Reprints: Tom Palmisano, P.O. Box 691732, Los Angeles, CA 90069, 323-655-5811.

© 2003 The Society for Investigative Dermatology. All rights reserved. With the exception of fair dealing for the purposes of research or private study, or criticism or review, no part of this publication may be reproduced, stored or transmitted in any form or by any means without the prior permission in writing from the copyright holder. Authorisation to photocopy items for internal and personal use is granted by the copyright holder for libraries and other users of the Copyright Clearance Center (CCC), 222 Rosewood Drive, Danvers, MA 01923, USA ([www.copyright.com](http://www.copyright.com)), provided the appropriate fee is paid directly to the CCC. This consent does not extend to other kinds of copying, such as copying for general distribution for advertising or promotional purposes, for creating new collective works or for resale.

All inquiries regarding copyrighted material from this publication, other than reproduction through the Copyright Clearance Center, should be directed to: Rights and Permissions Department, Blackwell Publishing, Inc., Commerce Place, 350 Main Street, Malden, MA 02148. FAX: (781) 388-8255.

No responsibility is assumed by the Publisher or Societies for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. No suggested test or procedure should be carried out unless, in the reader's judgment, its risk is justified. Because of rapid advances in the medical sciences, we recommend that independent verification of diagnoses and/or drug dosages should be made. Discussions, views and recommendations as to medical procedures, choice of drugs and drug dosages are the responsibility of the authors.